Vnitr Lek 2013, 59(5):366-369

Combined therapy of arterial hypertension

H. Rosolová
Centrum preventivní kardiologie II. interní kliniky Lékařské fakulty UK a FN Plzeň, přednosta prof. MUDr. Jan Filipovský, CSc.

For a successful treatment of arterial hypertension, in most patients it is necessary to prescribe at least two antihypertensive medicines. A well chosen fixed combination of antihypertensives improves lifelong compliance with treatment, another important approach to improving treatment compliance being regular education of the patient regarding the appropriateness of regular medicine taking in relation to the risks of untreated hypertension. Currently, when initiating treatment of uncomplicated hypertension, the combination of diuretics with beta-blockers is being abandoned, especially for their metabolic adverse effects. The most frequent combination of recommended antihypertensive medicinal products is a combination of renin-angiotensin system inhibitors, i.e. ACE inhibitors or sartans, with calcium channel blockers or diuretics. Some studies about the efficacy of this modern combined antihypertensive therapy are mentioned.

Keywords: treatment of arterial hypertension; fixed combination; compliance with treatment; telmisartan; thiazide diuretics

Received: March 4, 2013; Accepted: March 8, 2013; Published: May 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosolová H. Combined therapy of arterial hypertension. Vnitr Lek. 2013;59(5):366-369.
Download citation

References

  1. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-719. Go to original source... Go to PubMed...
  2. Vrijens B, Vincze G, Kristanto P et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336: 1114-1117. Go to original source... Go to PubMed...
  3. Filipovský J, Widimský jr. J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58: 785-801. Go to PubMed...
  4. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122: 290-300. Go to original source... Go to PubMed...
  5. Dahlhof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regiment of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure LOwering Arm (ASCOT - BPLA): a multicenter rendomised controlled trial. Lancet 2005; 364: 1-12. Go to original source... Go to PubMed...
  6. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-2597. Go to original source... Go to PubMed...
  7. Messerli FH, Makani H, Benjo A et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol 2011; 57: 590-600. Go to original source... Go to PubMed...
  8. Dorsch M, Gillespie BW, Erickson SR et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57: 689-694. Go to original source... Go to PubMed...
  9. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766. Go to original source... Go to PubMed...
  10. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique antagonist with selective PPAR gamma modulating activity. Hypertension 2004; 43: 993-1002. Go to original source... Go to PubMed...
  11. Schumacher H, Mancia G The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008; 1: 32-40. Go to original source... Go to PubMed...
  12. Abe M, Okada K, Maruyama T et al. Blood pressure lowering and antiproteinuric effect of switching from high-dose ARBs to normal-dose telmisartan and low-dose hydrochlorothiazide in hypertensive patients with chronic kidney disease. Int J Clin Pharmacol Ther 2010; 48: 206-213. Go to original source... Go to PubMed...
  13. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961. Go to original source... Go to PubMed...
  14. Neutel JM, Littlejohn TW, Chrysant SG et al. Telmisartan/Hydrochlorothiatzide in comparison with losartan/Hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hyperstens Res 2005; 28: 555-563. Go to original source... Go to PubMed...
  15. White WB, Lacourciere Y, Davidal G. Effect of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347-353. Go to original source... Go to PubMed...
  16. Marfatia R, White WB, Schumacher H. Effects of Telmisartan with Hydrochlorothiazide versus Valsartan with Hydrochlorothiazide in patients with moderate-to-severe hypertension. Intern J Hypertens 2012; doi:101155/2012/976828. Go to original source... Go to PubMed...
  17. Yusuf S, Teo K, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
  18. Masayoshi Kojima, Masuo Ohashi, Yasuaki Dohi et al. Titration of telmisartan, but not addition of amlodipin, reduces urine albumin in diabetic patients treated with telmisartan-diuretic. J Hypertens 2013; 31: 186-191. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.